-
Zevra Therapeutics NasdaqGS:ZVRA Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Location: 1180 Celebration Boulevard, Celebration, FL, 34747, United States | Website: https://zevra.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
472.7M
Cash
62.63M
Avg Qtr Burn
-15.43M
Short % of Float
13.07%
Insider Ownership
0.62%
Institutional Own.
65.42%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AZSTARYS (KP415) (serdexmethylphenidate and dexmethylphenidate) Details Attention deficit hyperactivity disorder | Approved Quarterly sales | |
MIPLYFFA™ (arimoclomol) Details Rare genetic disease, Rare diseases, Niemann Pick Disease Type C | Approved Quarterly sales | |
Approved Quarterly sales | ||
Celiprolol Details Vascular Ehlers-Danlos Syndrome | Phase 3 Data readout | |
KP1077 (serdexmethylphenidate, SDX) Details EDS in Idiopathic Hypersomnia
| Phase 2 Update | |
KP1077 (serdexmethylphenidate, SDX) Details Narcolepsy, Sleeping disorder | Phase 1 Data readout | |
KP879 (Methylphenidate) Details Stimulant Use Disorder | Phase 1 Update |